Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout by Nick Paul Taylor Friday, January 10, 2020 The takeover, which values Dermira at just a whisker above its closing price yesterday, comes months after the biotech posted phase 2b data.
Pfizer's JAK inhibitor hits the mark in another eczema trial by Amirah Al Idrus Friday, September 27, 2019 Pfizer’s JAK inhibitor cleared patients’ skin and improved atopic dermatitis symptoms in a second phase 3 study.
Almirall pays Dermira $50M for European rights to Dupixent rival by Amirah Al Idrus Tuesday, June 25, 2019 Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.
Dermira dumps acne drug after phase 3 flubs by Amirah Al Idrus Monday, March 5, 2018 Dermira pulled the plug on olumacostat glasaretil when it failed to beat out placebo.
Roche in part-sale of mixed bag lebrikizumab to Dermira by Ben Adams Tuesday, August 8, 2017 Dermira will take on certain rights to lebrikizumab from Roche.
Dermira posts broadly positive results for excessive sweat drug by Ben Adams Thursday, June 2, 2016 The Californian biotech Dermira says its experimental sweat drug DRM04 passed one Phase III test but narrowly missed its target on a second--although analysts believe this will still be good enough to reap an FDA approval.
